Why the study?
Does intraarterial chemoradiotherapy increase the risk of cerebral infarction compared to intravenous chemoradiotherapy in patients with head and neck cancer?
Does intraarterial chemoradiotherapy increase the risk of cerebral infarction compared to intravenous chemoradiotherapy in patients with head and neck cancer?
Intraarterial chemoradiotherapy for head and neck cancer is associated with a significantly higher risk of cerebral infarction compared to intravenous administration.
Answers are grounded in this paper and cite their sources.
Intraarterial CRT may warrant caution in head and neck cancer; hypothesis-generating and requires randomized confirmation.
BACKGROUND: The occurrence of cerebral infarction after intraarterial chemoradiotherapy (CRT) remains uncertain. METHODS: We conducted a retrospective cohort study using the Diagnosis Procedure Combination (DPC) database from 2010 to 2013. We performed a 1:4 propensity score-matched analysis between patients undergoing intraarterial or intravenous CRT, and determined the association between cerebral infarction and intraarterial CRT. RESULTS: Among patients with head and neck cancer receiving platinum-based chemotherapy and concurrent radiotherapy, we identified 776 patients with intraarterial CRT and 7157 with intravenous CRT. The occurrence of cerebral infarction was significantly higher in the intraarterial CRT group than in the intravenous CRT group: 1.4% (11 of 775) versus 0.4% (12 of 3100; p = .002). There was no significant difference in mucosal toxicity or febrile neutropenia. CONCLUSION: About 10% of patients received intraarterial CRT. Intraarterial CRT was associated with a higher incidence of cerebral infarction than was intravenous CRT. This result is useful when considering the procedure-related risks and the potential benefits of intraarterial CRT.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: